公开(公告)号：US20210238564A1

公开(公告)日：2021-08-05

申请号：US17273880

申请日：2019-09-03

Applicant: The Board of Regents of the University of Texas System

Inventor： Jerry W. SHAY ,  Enzo TEDONE ,  Mohammed E. SAYED

IPC: C12N9/12 ,  G01N33/50

Abstract: The present disclosure describes purified telomerase holoenzyme and its delivery to cells, such as T cells, for increasing telomere length, increasing cell proliferation, and impeding cell senescence.

公开(公告)号：US20190298751A1

公开(公告)日：2019-10-03

申请号：US16304538

申请日：2017-05-26

Applicant: The Board of Regents of the University of Texas System ,  The Wistar Institute of Anatomy and Biology

Inventor： Jerry W. SHAY ,  Gao ZHANG

IPC: A61K31/7076 ,  A61P35/00

Abstract: The present disclosure provide for methods of using 6-thio-2′-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.

公开(公告)号：US20240009223A1

公开(公告)日：2024-01-11

申请号：US18329381

申请日：2023-06-05

Applicant: The Board of Regents of The University of Texas System ,  The Wistar Institute of Anatomy and Biology

Inventor： Jerry W. SHAY ,  Gao ZHANG

IPC: A61K31/7076 ,  A61P35/00 ,  A61K45/06 ,  A61K31/506

CPC classification number: A61K31/7076 ,  A61P35/00 ,  A61K45/06 ,  A61K31/506

Abstract: The present disclosure provide for methods of using 6-thio-2′-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.